The MARS feasibility trial: Conclusions not supported by data

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1093-1094

  Weder, Walter ^a   Stahel, Rolf A ^a   Baas, Paul ^b   Dafni, Urania ^c   de Perrot, Marc ^d,e   McCaughan, Brian C ^e   Nakano, Takashi ^f   Pass, Harvey I ^g   Robinson, Bruce WS ^h   Rusch, Valerie W ⁱ   Sugarbaker, David J ^j   van Zandwijk, Nico ^k  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF TORONTO   (Canada)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; EXTRAPLEURAL PNEUMONECTOMY; HUMAN; LETTER; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

FEMALE; HUMANS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; PNEUMONECTOMY;

EID: 81255176812     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70307-2     Document Type: Letter

References (7)

1. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451-3457.
2. Weder W, Stahel R, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202. for the Swiss Group for Clinical Cancer Research.
3. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007, 57:89-95.
4. Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008, 3:499-504.
5. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:3007-3013.
6. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010, 36:1362-1369. for the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group.
7. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011, 12:763-772.